KEGG   DISEASE: Fallopian tube cancer
Entry
H01554                      Disease                                

Name
Fallopian tube cancer
Description
Fallopian tube cancer is a rare, aggressive gynecologic malignancy. Recent genetic and immunohistochemical studies strongly suggest that high-grade serous adenocarcinoma (SAC) involving the ovary likely arises from distal fallopian tube epithelium, indicating that some ovarian cancers develop in the fallopian tube and are then spread to the ovary. Fallopian tube cancers are similar to ovarian cancer with respect to the proportion of tumors with abnormal expression of c-erbB-2 and p53. It has been proposed that the p53 signature is the earliest step in the pathogenesis of fallopian tube cancer. In this model, tubal epithelium on the fimbria experiences genotoxic damage and, as a result, the secretory cell exhibits over-accumulation of p53 protein (p53 signature). There is also some evidence that BRCA-1 and BRCA-2 mutations and c-myc have a major role in tumorgenesis.
Category
Cancer
Brite
Human diseases [BR:br08402]
 Cancers
  Cancers of the breast and female genital organs
   H01554  Fallopian tube cancer
Human diseases in ICD-11 classification [BR:br08403]
 02 Neoplasms
  Malignant neoplasms, except of lymphoid, haematopoietic, central nervous system or related tissues
   Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues
    Malignant neoplasms of female genital organs
     2C74  Malignant neoplasms of fallopian tube
      H01554  Fallopian tube cancer
Gene
BRCA1 (mutation) [HSA:672] [KO:K10605]
BRCA2 (mutation) [HSA:675] [KO:K08775]
TP53 (overexpression) [HSA:7157] [KO:K04451]
ERBB2 (overexpression) [HSA:2064] [KO:K05083]
c-myc (overexpression) [HSA:4609] [KO:K04377]
Drug
Bevacizumab [DR:D06409]
Niraparib tosilate hydrate [DR:D11895]
Other DBs
ICD-11: 2C74
ICD-10: C57.0
MeSH: D005185
Reference
PMID:25286779 (marker)
  Authors
Horng HC, Teng SW, Huang BS, Sun HD, Yen MS, Wang PH, Tsui KH, Wen KC, Chen YJ, Chuang CM, Chao HT, Chang WH
  Title
Primary fallopian tube cancer: domestic data and up-to-date review.
  Journal
Taiwan J Obstet Gynecol 53:287-92 (2014)
DOI:10.1016/j.tjog.2014.07.003
Reference
PMID:23622731 (description, gene, marker, drug)
  Authors
Kalampokas E, Kalampokas T, Tourountous I
  Title
Primary fallopian tube carcinoma.
  Journal
Eur J Obstet Gynecol Reprod Biol 169:155-61 (2013)
DOI:10.1016/j.ejogrb.2013.03.023
Reference
  Authors
Nik NN, Vang R, Shih IeM, Kurman RJ
  Title
Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma.
  Journal
Annu Rev Pathol 9:27-45 (2014)
DOI:10.1146/annurev-pathol-020712-163949
Reference
  Authors
Haruta S, Furukawa N, Yoshizawa Y, Tsunemi T, Nagai A, Kawaguchi R, Tanase Y, Yoshida S, Kobayashi H
  Title
Molecular genetics and epidemiology of epithelial ovarian cancer (Review).
  Journal
Oncol Rep 26:1347-56 (2011)
DOI:10.3892/or.2011.1456
Reference
PMID:24511245 (gene, drug)
  Authors
Sama AR, Schilder RJ
  Title
Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.
  Journal
Int J Womens Health 6:149-57 (2014)
DOI:10.2147/IJWH.S40889
Reference
PMID:7773939
  Authors
Lacy MQ, Hartmann LC, Keeney GL, Cha SC, Wieand HS, Podratz KC, Roche PC
  Title
c-erbB-2 and p53 expression in fallopian tube carcinoma.
  Journal
Reference
  Authors
Vang R, Shih IeM, Kurman RJ
  Title
Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.
  Journal
Histopathology 62:44-58 (2013)
DOI:10.1111/his.12046
Reference
PMID:25315029 (drug)
  Authors
Keating GM
  Title
Bevacizumab: a review of its use in advanced cancer.
  Journal
Drugs 74:1891-925 (2014)
DOI:10.1007/s40265-014-0302-9
LinkDB

» Japanese version

DBGET integrated database retrieval system